

Tel:+86-571-89028388 Fax: +86-571-89028228 Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 1 of 11

COVID-19 Antigen Rapid Test (Latex) Performance Validation Report

Prepared By: Yanhua ZHANG Date: 02/09/2020

Reviewed By: Qian XU Date: 02/09/2020

Approval By: Zhong WANG Date: 03/09/2020



Tel:+86-571-89028388 Fax: +86-571-89028228 Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 2 of 11

1. Review overall product performance vs. targeted performance goals

| Co | ndition | Accepted standards | | | | |
|---|-----------------|---|--|--|--|--|
| Limit o | f Detection | Positive detection rate≥95% | | | | |
| Positive co | pincidence rate | no negative results | | | | |
| Negative co | oincidence rate | no positive results | | | | |
| Cross- | -reactivity | no Cross-reactivity | | | | |
| Inte | rference | no differences | | | | |
| D | Intra assay | No distinct difference was detected in intra lots | | | | |
| Precision Inter assay No significant differences were detected between bate | | | | | | |

2. Limit of Detection

2.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

2.2 Method:

Use COVID-19 Antigen Rapid Test (Latex) product to detect spike negative sample into buffer, respectively. Prepare the supernatant for subsequent use. Spiked a group of serially diluted SARS-COV-2 spike glycoprotein(40ng/mL, 20ng/mL, 10ng/mL, 5ng/mL, 2.5ng/mL, 0ng/mL) in supernatant described above, respectively. Each supernatant are tested 20 times.

2.3 Results:

According to the standard procedure of reagent use operation, the results are read in 15 minutes and repeated 20 times.

The results are as follows ("+" indicates a positive result, "-" indicates a negative result):



Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 3 of 11

| LOT | LC | LCOVADEV001 LCOVADEV002 LCOVADEV003 | | | LCOVADEV002 | | | 003 | |
|-----------------|-------|-------------------------------------|-------|-------|-------------|-------|-------|-------|-------|
| Repeat Times | 1 | 2 | 3 | 1 | 2 | 3 | 1 | 2 | 3 |
| 40ng/mL | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 |
| 20ng/mL | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 |
| 10ng/mL | 19/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 20/20 | 19/20 | 20/20 |
| 5ng/mL | 19/20 | 20/20 | 20/20 | 20/20 | 20/20 | 19/20 | 20/20 | 20/20 | 20/20 |
| 2.5ng/mL | 11/20 | 9/20 | 13/20 | 8/20 | 10/20 | 12/20 | 14/20 | 11/20 | 13/20 |
| 0 ng/mL | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 | 0/20 |

2.4 Conclusion:

By the above experimental results it can be seen that the limit of detection (LOD) of COVID-19 Antigen Rapid Test (Latex) is 5ng/mL SARS-COV-2 spike glycoprotein.

3. Positive coincidence rate

3.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

3.2 Method

Use COVID-19 Antigen Rapid Test (Latex) product to detect the positive L, M, H quality control products as the evaluation sample, and each batch of reagents is tested, and the results are required to be positive.

3.3 Results:

According to the standard procedure of reagent use operation, the results are read in 15 minutes and repeated 3 times.

The results are as follows ("+" indicates a positive result, "-" indicates a negative result):

| LOT | LCOVADEV001 | | | LCOVADEV002 | | | LCOVADEV003 | | |
|-----------------|-------------|---|---|-------------|---|---|-------------|---|---|
| Repeat Times | L | M | Н | L | M | Н | L | M | Н |
| 1 | + | + | + | + | + | + | + | + | + |
| 2 | + | + | + | + | + | + | + | + | + |
| 3 | + | + | + | + | + | + | + | + | + |



Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 4 of 11

3.4 Conclusion

By the above experimental results it can be seen that the positive control of COVID-19 Antigen Rapid Test (Latex) can reliably detect positive results, the positive compliance rate meets the requirements, and the results of the three batches of reagents can be satisfied.

4. Negative coincidence rate

4.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

4.2 Method

Use COVID-19 Antigen Rapid Test (Latex) product to detect the negative sample as the evaluation sample, each batch of reagents was repeatedly tested 1 time for the negative quality control characters, and the results are supposed to be all negative.

4.3 Results:

According to the standard procedure of reagent use operation, the results are read in 15 minutes and 1 time.

The results are as follows:

| Lot | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |
|--------------------------|-------------|-------------|-------------|
| Negative Quality Control | | | |
| N1 | - | - | - |
| N2 | - | - | - |
| N3 | - | - | - |
| N4 | - | - | - |
| N5 | - | - | - |
| N6 | - | - | - |
| N7 | - | - | - |
| N8 | - | - | - |

4.4 Conclusion

By the above experimental results it can be seen that the negative control of COVID-19 Antigen Rapid Test (Latex) can reliably detect negative results, the negative compliance rate meets the requirements, and the results of the three batches of reagents can be satisfied.

JOINSTAR Add: NO.519 Xingguo RD. Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang, China

Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 5 of 11

5. Cross-reactivity

5.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

5.2 Method

Spike negative sample into buffer, respectively. Prepare the supernatant for subsequent use. And use different concentrations of the recombinant protein of the coronavirus to conduct experiments to test its performance. Ten kinds of recombinant proteins of samples are spiked in supernatant described above, respectively.

| Concentration of Recombinant Proteins(µg/ml) |
|--|
| SARS-CoV-2 S1 Protein |
| SARS-CoV-2 S1 Protein(D614G) |
| SARS-CoV S1 Protein |
| HCoV-NL63 S1 Protein |
| HCoV-229E S1 Protein |
| HCoV-HKU1 S1 Protein |
| MERS-CoV S1 Protein |
| Human RSV (B1) G Protein |
| Influenza A H1N1 HA Protein |
| Influenza B HA Protein |

5.3 Results:

Follow the standard operating procedures for reagent use and read the results in 15 minutes. The results are as follows ("+" indicates a positive result, "-" indicates a negative result):

LCOVADEV001

| Concentration of Recombinant Proteins(µg/ml) | 0 | 0.001 | 0.01 | 0.1 | 1 | 10 |
|--|---|-------|------|-----|-----|-----|
| SARS-CoV-2 S1 Protein | - | - | + | ++ | +++ | +++ |
| SARS-CoV-2 S1 Protein(D614G) | - | + | + | ++ | +++ | +++ |
| SARS-CoV S1 Protein | - | - | ı | ı | - | ı |
| HCoV-NL63 S1 Protein | - | - | 1 | - | - | 1 |
| HCoV-229E S1 Protein | - | - | 1 | 1 | - | 1 |
| HCoV-HKU1 S1 Protein | - | _ | - | - | _ | 1 |
| MERS-CoV S1 Protein | - | - | - | - | - | - |



Tel:+86-571-89028388 Fax: +86-571-89028228 Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 6 of 11

| | | | | | | 0 | |
|-----------------------------|---|---|---|---|---|---|--|
| Human RSV (B1) G Protein | - | - | - | - | • | 1 | |
| Influenza A H1N1 HA Protein | - | - | - | - | - | 1 | |
| Influenza B HA Protein | - | - | - | - | - | 1 | |

LCOVADEV002

| Concentration of Recombinant Proteins(µg/ml) | 0 | 0.001 | 0.01 | 0.1 | 1 | 10 |
|--|---|-------|------|-----|-----|-----|
| SARS-CoV-2 S1 Protein | - | - | + | ++ | +++ | +++ |
| SARS-CoV-2 S1 Protein(D614G) | - | + | + | ++ | +++ | +++ |
| SARS-CoV S1 Protein | - | - | 1 | 1 | - | 1 |
| HCoV-NL63 S1 Protein | - | - | - | - | - | - |
| HCoV-229E S1 Protein | - | - | - | - | - | - |
| HCoV-HKU1 S1 Protein | - | - | - | - | - | - |
| MERS-CoV S1 Protein | - | - | - | - | - | - |
| Human RSV (B1) G Protein | - | - | - | - | - | - |
| Influenza A H1N1 HA Protein | - | - | - | - | - | - |
| Influenza B HA Protein | - | - | - | - | - | - |

LCOVADEV003

| Concentration of Recombinant Proteins(µg/ml) | 0 | 0.001 | 0.01 | 0.1 | 1 | 10 |
|--|---|-------|------|-----|-----|-----|
| SARS-CoV-2 S1 Protein | - | - | + | ++ | +++ | +++ |
| SARS-CoV-2 S1 Protein(D614G) | - | + | + | ++ | +++ | +++ |
| SARS-CoV S1 Protein | - | - | 1 | 1 | - | 1 |
| HCoV-NL63 S1 Protein | - | - | - | - | - | - |
| HCoV-229E S1 Protein | - | - | 1 | 1 | - | 1 |
| HCoV-HKU1 S1 Protein | - | - | 1 | 1 | - | 1 |
| MERS-CoV S1 Protein | - | - | - | - | - | - |
| Human RSV (B1) G Protein | - | - | 1 | 1 | - | 1 |
| Influenza A H1N1 HA Protein | - | - | - | - | - | - |
| Influenza B HA Protein | - | - | - | - | - | - |

5.4 Conclusion

The results show specific response to the S protein of SARS-CoV-2, and showed better specificity of some mutation novel coronavirus (such as D614G, the surface S protein increases, and the infection ability is enhanced) has increased. But it does not cross-react with other coronaviruses, such as SARS-CoV.

6. Interference test

6.1 Materials:

JOINSTAR Add: NO.519 Xingguo RD. Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang, China

Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 7 of 11

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |
| 23 1/Kil | | | |

6.2 Method:

Spike negative sample and control product sample into buffer, respectively. Prepare the supernatant for subsequent use. Combined with the actual situation of clinical samples, potential interfering substances in positive and negative samples, includ Hemoglobin, unconjugated bilirubin triglycerides are spiked in supernatant described above, respectively.

| substance | concentration |
|---------------|---------------|
| Triglyceride | 50mg/dl |
| Hemoglobin | 1000mg/dl |
| Ascorbic Acid | 20mg/dl |
| Bilirubin | 60mg/dl |

The concentration of these substances is greater than the concentrations listed in the following table, Mix the interference substance with samples (Negative, positive samples) and repeat the test three times for each sample. Then use each batch of kits for testing to verify the interference of these common potential interfering substances in the test results of the COVID-19 Antigen Rapid Test (Latex).

6.3 Results

According to the standard procedure of reagent use operation, the results are read in 15 minutes and repeated 3 times. The results are as follows ("+" indicates a positive result, "-" indicates a negative result):

| Carlandana | | | Lo | t 1 | | | | | |
|---------------|---|----------|----|------------|----------|---|--|--|--|
| Substance | | Negative | | | positive | | | | |
| Triglyceride | - | - | - | + | + | + | | | |
| Hemoglobin | - | - | - | + | + | | | | |
| Ascorbic Acid | - | - | - | + | + | + | | | |
| Bilirubin | - | - | - | + | + | + | | | |
| G 1 4 | | | Lo | ot 2 | | | | | |
| Substance | | Negative | | positive | | | | | |
| Triglyceride | - | - | - | + | + | + | | | |
| Hemoglobin - | | - | - | + | + | + | | | |
| Ascorbic Acid | - | - | - | + | + | + | | | |

JOINSTAR Add: NO.519 Xingguo RD. Yuhang Economic and Technological Development Zone, Hangzhou, Zhejiang, China

Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Page 8 of 11

| Bilirubin | | | - | + | + | + | | | | |
|---------------|---|----------|---|----------|---|---|--|--|--|--|
| Carlandana | | Lot 3 | | | | | | | | |
| Substance | | Negative | | positive | | | | | | |
| Triglyceride | - | - | - | + | + | + | | | | |
| Hemoglobin | - | - | - | + | + | + | | | | |
| Ascorbic Acid | - | - | - | + | + | + | | | | |
| Bilirubin | - | - | - | + | + | + | | | | |

6.4 Conclusion

According to the results above, there are no obvious interference introduced by materials listed above to the COVID-19 Antigen Rapid Test (Latex).

7. Intra assay

7.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

7.2 Method:

Use COVID-19 Antigen Rapid Test (Latex) product to detect the company's internal quality control products and negative specimen as the evaluation sample, each batch of reagents is tested 10 times and runed individually on 3 separate days repeatedly to see the intra-batch differences of each batch of reagents.

7.3 Results:

Follow the standard operating procedures for reagent use and read the results in 15 minutes. The results are as follows ("+" indicates a positive result, "-" indicates a negative result): Day1 Operator 1

| | | LCOVA | DEV001 | | | LCOVA | DEV002 | | LCOVADEV003 | | | | | |
|-----|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|-------------|----------------|----------------|----------------|--|--|
| No. | Negat ive N | Positi ve L | Positi ve M | Positi ve H | Negat ive N | Positi ve L | Positi ve M | Positi ve H | Negat ive N | Positi ve L | Positi ve M | Positi ve H | | |
| 1 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 2 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 3 | - | + | + | + | - | + | + | + | - | - + | | + | | |
| 4 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 5 | - | + | + | + | - | + | + | + | - + | | + | + | | |
| 6 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 7 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 8 | - | + | + | + | - | + | + | + | - | + | + | + | | |



Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn Page 9 of 11

| 9 | - | + | + | + | - | + | + | + | - | + | + | + |
|----|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | • | + | + | + | • | + | + | + | - | + | + | + |
| 11 | • | + | + | + | ı | + | + | + | - | + | + | + |
| 12 | • | + | + | + | • | + | + | + | - | + | + | + |
| 13 | - | + | + | + | - | + | + | + | - | + | + | + |
| 14 | - | + | + | + | - | + | + | + | - | + | + | + |
| 15 | 1 | + | + | + | ı | + | + | + | - | + | + | + |
| 16 | • | + | + | + | ı | + | + | + | - | + | + | + |
| 17 | • | + | + | + | ı | + | + | + | - | + | + | + |
| 18 | • | + | + | + | ı | + | + | + | - | + | + | + |
| 19 | • | + | + | + | • | + | + | + | - | + | + | + |
| 20 | - | + | + | + | - | + | + | + | - | + | + | + |

Day3 Operator 2

| | | LCOVA | DEV001 | | | LCOVA | DEV002 | | | LCOVA | DEV003 | |
|-----|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| No. | Negat ive N | Positi ve L | Positi ve M | Positi ve H | Negat ive N | Positi ve L | Positi ve M | Positi ve H | Negat ive N | Positi ve L | Positi ve M | Positi ve H |
| 1 | - | + | + | + | - | + | + + + - + | | + - + | | + | + |
| 2 | - | + | + | + | - | + | + | + | - | + | + | + |
| 3 | - | + | + | + | - | + | + | + | - | + | + | + |
| 4 | - | + | + | + | - | + | + | + | - | + | + | + |
| 5 | - | + | + | + | - | + | + | + | - | + | + | + |
| 6 | - | + | + | + | - | + | + | + | - | + | + | + |
| 7 | - | + | + | + | - | + | + | + | - + + | | + | + |
| 8 | - | + | + | + | - | + | + | + | - | + | + | + |
| 9 | - | + | + | + | - | + | + | + | - | + | + | + |
| 10 | - | + | + | + | - | + | + | + | - | + | + | + |
| 11 | - | + | + | + | - | + | + | + | - | + | + | + |
| 12 | - | + | + | + | - | + | + | + | - | + | + | + |
| 13 | - | + | + | + | - | + | + | + | - | + | + | + |
| 14 | - | + | + | + | - | + | + | + | - | + | + | + |
| 15 | - | + | + | + | - | + | + | + | - | + | + | + |
| 16 | - | + | + | + | - | + | + | + | - | + | + | + |
| 17 | - | + | + | + | - | + | + | + | - | + | + | + |
| 18 | - | + | + | + | - | + | + | + | - | + | + | + |
| 19 | - | + | + | + | - | + | + | + | - | + | + | + |
| 20 | - | + | + | + | - | + | + | + | - | + | + | + |



Page 10 of 11

Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn

Day5 Operator 3

| | | LCOVA | DEV001 | | | LCOVA | DEV002 | | LCOVADEV003 | | | | | |
|-----|-------|--------|--------|--------|-------|--------|--------|--------|-------------|--------|--------|--------|--|--|
| No. | Negat | Positi | Positi | Positi | Negat | Positi | Positi | Positi | Negat | Positi | Positi | Positi | | |
| | ive N | ve L | ve M | ve H | ive N | ve L | ve M | ve H | ive N | ve L | ve M | ve H | | |
| 1 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 2 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 3 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 4 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 5 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 6 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 7 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 8 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 9 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 10 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 11 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 12 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 13 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 14 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 15 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 16 | - | + | + | + | - | + | + | + | - | - + | | + | | |
| 17 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 18 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 19 | - | + | + | + | - | + | + | + | - | + | + | + | | |
| 20 | - | + | + | + | - | + | + | + | - | + | + | + | | |

7.4 Conclusion

According to the results above, the intraassay precision of the product was no significant differences among the three batches of reagents.

8. Inter assay

8.1 Materials:

| Reagent name and specifications | Lot 1 | Lot 2 | Lot 3 |
|---|-------------|-------------|-------------|
| COVID-19 Antigen Rapid Test (Latex) 25T/Kit | LCOVADEV001 | LCOVADEV002 | LCOVADEV003 |

8.2 Method:

Use COVID-19 Antigen Rapid Test (Latex) product to detect the company's internal quality control products and negative specimen as the evaluation sample, the three batches of reagents were measured in parallel, and each quality control product was repeated 20 times to see the differences between the three batches of reagents.



Tel:+86-571-89028388 Fax: +86-571-89028228

Web: http://www.joinstar.cn Email: info@joinstar.cn Page 11 of 11

8.3 Results

Follow the standard operating procedures for reagent use and read the results in 15 minutes. The results are as follows ("+" indicates a positive result, "-" indicates a negative result):

| No | | | Negative N | | | Positive L | | osi | it | | osi | |
|----|-------|------|------------|----------|-------|------------|---|-----|----|---|-----|---|
| NO | Lot 1 | Lot2 | Lot3 | Lot 1 | Lot 2 | Lot3 | L | L | | | L | L |
| 1 | - | - | - | + | + | + | + | + | + | + | + | + |
| 2 | - | - | • | + | + | + | + | + | + | + | + | + |
| 3 | - | - | • | + | + | + | + | + | + | + | + | + |
| 4 | - | - | - | + | + | + | + | + | + | + | + | + |
| 5 | - | - | - | + | + | + | + | + | + | + | + | + |
| 6 | - | - | - | + | + | + | + | + | + | + | + | + |
| 7 | - | - | - | + | + | + | + | + | + | + | + | + |
| 8 | - | - | - | + | + | + | + | + | + | + | + | + |
| 9 | - | - | - | + | + | + | + | + | + | + | + | + |
| 10 | - | - | - | + | + | + | + | + | + | + | + | + |
| 11 | - | - | - | + | + | + | + | + | + | + | + | + |
| 12 | - | - | - | + | + | + | + | + | + | + | + | + |
| 13 | - | - | - | + | + | + | + | + | + | + | + | + |
| 14 | - | - | - | + | + | + | + | + | + | + | + | + |
| 15 | - | - | - | + | + | + | + | + | + | + | + | + |
| 16 | - | - | - | + | + | + | + | + | + | + | + | + |
| 17 | - | - | - | + | + | + | + | + | + | + | + | + |
| 18 | - | - | - | + | + | + | + | + | + | + | + | + |
| 19 | - | - | - | + | + | + | + | + | + | + | + | + |
| 20 | - | - | - | + | + | + | + | + | + | + | + | + |

8.4 Conclusion

According to the results above, the intraassay precision of the product was no significant differences among the three batches of reagents.